Averin Capital Acquisition Corp.: insider trades · United States · SEC (Form 4)

About Averin Capital Acquisition Corp.

Averin Capital Acquisition Corp. (ticker: ACAAU) is a U.S.-listed SPAC trading on the Nasdaq Global Market in the United States. In economic substance, it is a blank-check company formed to pursue a merger, share exchange, asset acquisition, or similar business combination with one or more private operating businesses. That means the company is not, at this stage, a traditional operating issuer with sales, margins, or product revenue; it is a listed acquisition vehicle whose future value will depend on the quality and timing of its eventual deal. The company was incorporated as a Cayman Islands exempted company on October 17, 2025, and its initial strategic focus is the intersection of technology and health. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2096900/000121390026017987/ea0265589-04.htm)) From a capital-markets perspective, Averin completed its initial public offering on February 20, 2026, raising $250 million through the sale of 25,000,000 units at $10.00 per unit. The units began trading on February 19, 2026 under ACAAU, and separate trading in the underlying securities was approved to begin on April 10, 2026. After separation, the Class A ordinary shares are expected to trade as ACAA and the warrants as ACAAW on Nasdaq. Each unit contains one Class A ordinary share and one-sixth of one redeemable warrant, with a full warrant exercisable at $11.50 per share. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2096900/000121390026018849/ea027779502ex99-2_averin.htm)) Averin’s competitive position should be assessed less by current operations and more by sponsor quality, execution discipline, and the credibility of its post-IPO acquisition strategy. As disclosed in its prospectus, the company had not selected a target and had not entered into substantive discussions with any potential business combination partner at the time of filing. It has stated that it intends to concentrate its efforts on businesses at the intersection of technology and health, suggesting a preference for companies with durable growth potential, data-enabled workflows, or healthcare-related digital platforms. That target preference provides some strategic framing, but the investment case remains event-driven and highly dependent on future transaction selection. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2096900/000121390026017987/ea0265589-04.htm)) The company’s operational base is in New York, New York, reinforcing its positioning within the U.S. financial ecosystem. For investors in France, Belgium, and Switzerland, the key point is that ACAAU is best understood as a transaction-driven special purpose acquisition company rather than an operating healthcare or technology business. Recent public disclosures in SEC filings have focused on the IPO, the trust account structure, and the mechanics of unit separation, not on commercial product launches or operating metrics. In other words, the near-term story is corporate finance and deal execution, not fundamentals from an established operating franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1204876/000121390026023169/xslF345X05/ownership.xml?utm_source=openai))